Clinical Trials Browser

Phase 1/2 × Inflammatory Breast Neoplasms × Clear all

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Phase 1/2 Active not recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Inflammatory Breast Neoplasms

NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

9 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00450892 2016-07-07

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00070252 2015-05-04

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00004925 2013-06-19

Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms